StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
1817.TW$39.45-0.25%
Fair $39.45+0.0%

1817.TW

Sanitar Co., Ltd.

Consumer Defensive / Household & Personal ProductsTaiwan

$39.45

-0.10 (-0.25%)

Fairly Valued+0.0%Fair Value $39.45Fund rank 38/100 · Data gapFallback financials|
SA 54/C
F-Score: 4/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 24% · confianza 25%

FCF escenarios

weak_data · normalized FCF $299.4M · quality 82.3/100

Data gap 38/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 78/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

54/100

C

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 1817.TWLocal privado en este navegador · Sanitar Co., Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$2.9B

P/E

11.0x

↓

EV/EBITDA

5.8x

↓

ROE

11.7%

↑

Gross Margin

36.8%

↑

Debt/Equity

0.08

↓
52-Week Range$39
$37$46

TradingView lightweight chart

1817.TW price, volumen y niveles de valoración

Último $39.45Periodo +43.6%
Fair value: $39.45

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-0.6%

FCF CAGR

+8.5%

FCF margin

16.1%

FCF / Net income

1.60x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $2.62B · net income $262.2M · FCF $420.4M

2022-FY → 2025-FY

Gross margin

36.8%+2.4% pts

Operating margin

13.6%-0.3% pts

Net margin

10.0%-0.9% pts

FCF margin

16.1%+3.7% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$2.62B$2.62B$2.79B$2.50B$2.67B
Net Income$262.2M$262.2M$315.2M$235.6M$290.8M
EBITDA$457.4M$457.4M$521.6M$427.3M$507.1M
EPS——4.333.254.01
Gross Margin36.8%36.8%35.5%34.3%34.4%
Operating Margin13.6%13.6%13.5%11.5%13.9%
Net Margin10.0%10.0%11.3%9.4%10.9%
Balance Sheet
Debt/Equity0.080.080.050.100.11
Current Ratio6.156.15———
Cash Flow
Free Cash Flow$420.4M$420.4M$249.9M$299.4M$329.5M
Returns
ROE11.7%11.7%14.0%11.7%14.6%
Valuation
P/E10.9910.999.5311.299.73
EV/EBITDA5.815.815.486.025.54
P/B1.271.271.341.331.42
Growth & Yield
Revenue Growth-6.2%-6.2%11.6%-6.3%—
EPS Growth——33.2%-19.0%—
Dividend Yield6.1%6.1%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -4.7%

Total return

-4.7%

Start / end P/E

n/dx → n/dx

EPS bridge

4.33 → n/d

Residual

-10.7%

EPS growthn/d
Multiple reratingn/d
Dividend+6.1%
Residual / FX / buybacks / cross-term-10.7%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.